Best Life Sciences Companies in Guangdong, China
The 51 best Life Sciences companies in Guangdong, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Guangzhou Kang Liming Biotechnology.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Guangdong
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Apex Tools & Orthopedics Develops Orthopedic devices and instruments | — | — | Deadpooled | 2004 | Scott Liang CEO & GM | — | — | — |
| 2 | bebetter med Bebetter Med operates as a pharmaceutical research and development enterprise with a focus on small molecule… | — | — | PE-Backed | 2012 | — | 87 | — | — |
| 3 | Beijing Intemet Technology Provider of AI-based pathological diagnosis platform | — | — | Funding Raised | 2018 | Zhang Kaiwen Co-Founder & CEO | — | — | — |
| 4 | Biotyx Medical Developer of cardiovascular medical devices | — | — | Funding Raised | 2019 | Zhang DeYuan Founder & CEO | — | 149 patents Absorbable metal stents and related manufacturing, polishing, and straightening technologies. | 1 launch |
| 5 | bostal drug delivery Bostal Drug Delivery develops and manufactures drug preparation products for new drug delivery systems. | — | — | Private | 2013 | — | 400 | 9 patents Controlled-release drug delivery systems: microspheres, gels, films, and pellet formulations. | — |
| 6 | Chuanger Biotechnology Provider of collagen-based wound-care products | — | — | Funding Raised | 2002 | Tong Gang CEO | — | — | — |
| 7 | Chuangxin International Biotechnology Provider of organoid models for drug discovery and development | — | — | Funding Raised | 2016 | Huang Min Founder & CEO | 45 | — | — |
| 8 | Daan Gene Provider of instruments, reagents, and services in molecular diagnostics | — | — | Public | 1993 | Yang Wang CEO | 3,580 | 115 patents Engineered enzymes and kits for nucleic‑acid amplification and viral diagnostic testing | — |
Top 12 Life Sciences companies in Guangdong
#1
Series C · Guangzhou, Guangdong · founded 2013 · 150 employees$45Mraised▾
Guangzhou Zhiyi Biotechnology is developing second-generation probiotics. The lead candidate of the company AAD/CDAD (Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea) for treating gastrointestinal disorders. The candidate is in the preclinical stage. Also, they are developing candidates for treating ulcerative colitis. They offer fermentation, separation of active products, etc.
- Mar 2024Series C—
- Jul 2022Series B$15M
- Sep 2021Series B—
- Dec 2020Series B$16.8M
#2
Series C · Guangzhou, Guangdong · founded 2003 · 600 employees$14Mraised▾
Developer of therapeutics for reproductive health. It offers drugs, topicals, latex products, and nutritional supplemnts for female, male, and assisted reproductive health.
- Jun 2023Series C$14M
#3
Series D · Guangzhou, Guangdong · founded 2015$219.7Mraised▾
Guangzhou Kang Liming Biotechnology provides cancer detection kits. Chang'an Heart, the company's platform product, is a fecal DNA colon cancer detection kit. The kit is meant for keeping the sample intact until it reaches the laboratory. The company also provides screening services for lung, gastric, and bladder cancer.
- Oct 2021Series D$87M
- Sep 2020Series C$88M
- Apr 2019Series B$44.7M
- Series A—
#4
Series D · Guangzhou, Guangdong · founded 2018$120.7Mraised▾
Provider of gene editing and sequencing technology for precision medicine. The company provides two propriety technology platforms, a diagnostic platform for genetic editing technology which is CRISPR based, and a high-throughput sequencing (NGS) platform. The company offers an AI-based big data muti-omics analyzing platform.
- Nov 2021Series D$46.9M
- Feb 2021Series C$31M
- Aug 2020Series B$28.8M
- Sep 2019Series A$14.1M
#5
Series A · Guangzhou, Guangdong · founded 2018$35Mraised▾
Developer of therapeutics for cancer treatment. It focuses on the development of innovative anti-tumor drugs. The lead candidate of the company includes "LP-108" for the treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL).
- Nov 2022Series A$35M
- Jul 2021Series A—
#6
Series B · Guangzhou, Guangdong · founded 2015 · 63 employees$50.2Mraised▾
Provider of diagnostic testing services for genetic analysis. The company provides testing services for genomic detection, hereditary metabolic disease, Epilepsy Comprehensive testing, and more. Also, it offers genetic counseling and clinical consultation.
- Jun 2022Series B$29.9M
- Jan 2020Series B$16M
- Oct 2019Series A$4.3M
#7
Series C · Shenzhen, Guangdong · founded 2015 · 18 employees$10Mraised▾
Developer of novel anti-cancer drug vectors. The company leverages delivery mechanisms and proprietary precise gene engineering technology to develop oncolytic virus products for cancer treatment.
- Oct 2022Series C—
- Dec 2020Series C—
- Sep 2020Series B$10M
#8
Series A · Guangzhou, Guangdong · founded 2018$14.8Mraised▾
Developer of immunotherapies for cancer. It offers a lead candidate CAN1012, a TLR7 agonist, and DPV-001 a dendritic cell targeted cancer vaccine that provides both innate and adaptive immune responses against tumor cells.
- Aug 2022Series A$14.8M
#9
Series C · Guangzhou, Guangdong · founded 2015 · 20 employees$73Mraised▾
Developer of high throughput gene sequencing platform for clinical application. It enables early diagnosis of genetic diseases and thereby intervene and reduce the incidence of the disease. Its proprietary test menu includes non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy tests.
- Feb 2021Series C$40M
- Nov 2017Series B$28M
- Dec 2015Series A$5M
#10
Public · Guangzhou, Guangdong · founded 2014 · 1138 employees$203.3Mraised▾
Developer of personalized diagnostic and treatment services based on genomic big data analysis. It provides next-generation sequencing-based cancer diagnostics, including bioinformatics analysis and tumor molecular pathology, and immunohistochemistry. Uses diagnostic tools to gather the information that enables the personalized treatment of cancer. It also offers liquid biopsy tests for lung cancer.
- Feb 2019Series C$127.5M
- Dec 2016Series B$43.1M
- Aug 2015Series A$23M
- 2014Series A$9.7M
#11
Public · Guangzhou, Guangdong · founded 2003 · 1189 employees$149Kraised▾
Developer of antibody drugs to treat multiple diseases. The company focuses on the research and development of a new generation of antibody drugs for the treatment of tumors, autoimmune diseases, cardiovascular diseases, and other major diseases. The company's product portfolio includes Glarely (adalimumab), Pubexi (bevacizumab), Serelil (Tocilizumab), and more.
- 2019Series C—
- 2018Series B—
- 2016Series A—
- Jun 2014Grant (prize money)$149K
#12
Series B · Longhua, Guangdong · founded 2020—raised▾
Developer of cardiac and neuro-interventional devices. The company develops neuro and cardiac interventional medical devices for doctors and patients including Cycas a distal embolic protection system and Campsis a microcatheter.
- Aug 2023Series B—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Guangdong is moving
A read on the academic research around Biotechnology in Guangdong — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 181 papers.
- Guangdong Academy of Agricultural Sciences30
- Guangdong Ocean University28
- Key Laboratory of Guangdong Province26
- Guangdong Medical College20
- Guangdong Academy of Sciences15
- Genome1→3
- Oxidative stress1→6
- Gene3
- Agriculture2
- Human health2
- Germplasm2
- In vitro2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.